

Viread® For Hepatitis B Registration In The Developing World

Approved

1. Argentina	May 2011	21. Ecuador	August 2012	41. Namibia	August 2015
2. Armenia	September 2011	22. Egypt	March 2012	42. Nepal	September 2014
3. Aruba	September 2011	23. El Salvador	December 2015	43. Niger	March 2014
4. Azerbaijan	May 2011	24. Ethiopia	August 2015	44. Pakistan	January 2013
5. Bangladesh	June 2011	25. Gabon	November 2014	45. Panama	February 2012
6. Belarus	December 2013	26. Georgia	June 2011	46. Paraguay	September 2011
7. Benin	April 2015	27. Guatemala	June 2011	47. Peru	June 2011
8. Bhutan	November 2012	28. Guinea	February 2014	48. Philippines	March 2014
9. Bolivia	September 2011	29. Honduras	July 2012	49. Senegal	February 2017
10. Brazil	December 2010	30. India	December 2011	50. Sint Maarten	June 2016
11. Burkina Faso	September 2014	31. Ivory Coast	November 2016	51. South Africa	February 2017
12. Cameroon	January 2016	32. Kenya	September 2014	52. Tanzania	August 2015
13. Central African Republic	January 2015	33. Kyrgyzstan	July 2012	53. Thailand	May 2013
14. Chad	November 2016	34. Lao, People's Dem. Rep.	January 2013	54. Togo	November 2016
15. Chile	November 2011	35. Madagascar	October 2017	55. Turkmenistan	April 2014
16. Colombia	March 2013	36. Mali	November 2014	56. Uganda	February 2017
17. Congo, Republic of the	November 2016	37. Mauritania	November 2016	57. Ukraine	September 2012
18. Costa Rica	March 2013	38. Mexico	November 2012	58. Uruguay	April 2011
19. Curacao	October 2011	39. Moldova	January 2013	59. Uzbekistan	May 2011
20. Dominican Republic	April 2016	40. Mongolia	September 2014	60. Zambia	November 2015
				61. Zimbabwe	July 2015

Filed

1. Guyana	January 2012
2. Jamaica	January 2011
3. Malawi	April 2014
4. Nigeria	January 2016
5. Venezuela	April 2016

Terms and Definitions

Approved: Dossier submitted and approved by country or no formal regulatory process in place; approval confirmed by country.

Filed: Dossier submitted and review pending.

Note

There can be no guarantee that marketing approval for Viread® for the treatment of hepatitis B will be granted in any of the low- and middle-income countries where registration is pending; any marketing approval, if granted, may have significant limitations on its use.